Source-grounded facts extracted from Edgewise Therapeutics, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Edgewise Therapeutics, Inc. reported financial results for first quarter of 2026.
“Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today reported financial results for the first quarter of 2026 and recent business highlights.”
Behrad Derakhshan changed role as Chief Operating Officer at Edgewise Therapeutics, Inc..
“On January 8, 2025, the Board of Directors (the “ Board ”) of Edgewise Therapeutics, Inc. (the “ Company ”) promoted Behrad Derakhshan, Ph.D. to the role of Chief Operating Officer of the Company, effective immediately.”
Edgewise Therapeutics, Inc. terminated Common Stock Sales Agreement with BofA Securities, Inc. (effective 2024-05-10).
“In connection with the Company's entry into the Sales Agreement, on May 10, 2024, the Company delivered written notice to BofA Securities to terminate the Prior Sales Agreement pursuant to Section 11(b) thereof.”
Edgewise Therapeutics, Inc. entered into Sales Agreement with Leerink Partners LLC valued at up to $175,000,000 (effective 2024-05-10).
“On May 10, 2024, Edgewise Therapeutics, Inc. (the "Company") entered into a Sales Agreement (the "Sales Agreement") with Leerink Partners LLC ("Leerink") under which the Company may offer and sell shares of the Company's common stock, par value $0.0001 per share (the "Common Stock"), having aggregate sales proceeds of up to $175,000,000 (the "Shares"), from time to time, through an "at the market offering" program under which Leerink will act as sales agent.”
Edgewise Therapeutics, Inc. reported financial results for first quarter of 2024.
“On May 9, 2024, Edgewise Therapeutics, Inc. issued a press release announcing its financial results for the first quarter ended March 31, 2024.”
Arlene Morris was appointed as Director at Edgewise Therapeutics, Inc..
“On May 6, 2024, the Board of Directors (the “Board”) of Edgewise Therapeutics, Inc. (the “Company”) appointed Arlene Morris to serve (i) as a Class I director, with a term expiring at the Company’s 2025 annual meeting of stockholders, (ii) as a member of the Audit Committee of the Board (the “Audit Committee”), and (iii) as a member of the Compensation Committee of the Board (the “Compensation Committee”), replacing Peter Thompson as a member of the Audit Committee and Compensation Committee.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.